← All trials
NCT05689996
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Apr 30, 2023
- Completion date
- May 1, 2023
- First posted
- Jan 19, 2023
- Last posted
- Jan 19, 2023
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assiut UniversityLead sponsor
- Assiut UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.